Further Evidence That Lanreotide Reduces Liver Growth in Patients With Polycystic Liver Disease, But Not the End of the Story
Gastroenterology
.
2019 Aug;157(2):298-299.
doi: 10.1053/j.gastro.2019.06.002.
Epub 2019 Jun 29.
Authors
Frederik Temmerman
1
,
Frederik Nevens
2
Affiliations
1
Department of Gastroenterology and Hepatology, University Hospitals, KU Leuven, Leuven, Belgium.
2
Department of Gastroenterology and Hepatology, University Hospitals, KU Leuven, Leuven, Belgium. Electronic address: frederik.nevens@uzleuven.be.
PMID:
31260661
DOI:
10.1053/j.gastro.2019.06.002
No abstract available
Publication types
Editorial
Comment
MeSH terms
Cysts
Humans
Kidney Diseases*
Liver Diseases*
Peptides, Cyclic
Somatostatin / analogs & derivatives
Substances
Peptides, Cyclic
lanreotide
Somatostatin
Supplementary concepts
Polycystic liver disease